

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW. WHO.INT

 Tel. direct:
 +41 22 791 37 17

 Fax direct:
 +41 22 791 47 30

 E-mail :
 prequalassessment@who.int

 In reply please refer to:
 HA765-0/MS/FV

Your reference:

Mrs Sandhya Jadhav Macleods Pharmaceuticals Ltd R&D Center Mumbai Mahakali Caves Road, Shanti Nagar Andheri (East) / Mumbai 400093 Mumbai Maharashtra Inde

6 October 2020

Dear Mrs Jadhav,

## WHO Prequalification Unit– Medicines FPP Prequalification – Assessment completed – Efficacy & Safety

## Application number: HA765-0

Thank you for submitting the data and information requested for the assessment of the product dossier for the WHO Prequalification Unit – Medicines.

A team of evaluators recently assessed the dossier:

## • HA765 - Dolutegravir (Sodium) Tablet, Dispersible 10mg

As a result of this assessment, you are informed that the efficacy/safety part of the dossier is considered acceptable. Please note that the outcome of the assessment of quality part of the dossier may affect the final acceptability of the efficacy/safety part of the dossier.

Your cooperation is appreciated.

Yours sincerely,

Faled

Dr Matthias Stahl Team Lead, Medicines Assessment Team Prequalification Unit Regulation and Prequalification Department